A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

What this trial studies

Bladder cancer is the tenth most common malignancy worldwide. About 75 percent (%) of bladder cancers are non-muscle invasive at diagnosis with approximately 25% of NMIBC patients have HR, NMIBC. The TAR-200/gemcitabine (JNJ-17000139) product is an intravesical drug delivery system regulated as an investigational drug. The drug constituent consists of gemcitabine and osmotic minitablets. Cetrelimab (JNJ-63723283) is a fully human immunoglobulin G4 (IgG4) kappa monoclonal antibody (mAb) that binds programmed-cell death protein (PD)-1. The mainstay of treatment for HR-NMIBC is transurethral resection of bladder tumor, followed by intravesical treatment with BCG. In this study metronomic dosing of intravesical gemcitabine, delivered via TAR-200, alone or in combination with cetrelimab will be evaluated and compared against intravesical BCG. The study consists of a Screening phase, Treatment phase, and Follow-up phase. The total duration of the study will be up to 5 years and 2 months. Efficacy, Safety, pharmacokinetics (PK), and biomarkers will be assessed at specific time points during the study.

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed initial diagnosis by local pathology (within 90 days of the most recent signed informed consent) of high grade non-muscle invasive bladder cancer (HR-NMIBC) (high-grade Ta, any T1 or carcinoma in-situ \[CIS\]), in participants who are Bacillus Calmette Guérin (BCG)-naïve
* BCG-naïve (participants who have not received prior intravesical BCG or who previously received but stopped BCG more than 3 years before date of randomization are eligible)
* All visible papillary disease must be fully resected (absent) prior to date of randomization and documented at baseline cystoscopy. Local urine cytology at screening must be negative or atypical (for high-grade urothelial carcinoma \[HGUC\]) for patients with papillary only disease (without CIS)
* Eastern Cooperative Oncology Group (ECOG) performance status Grade 0, 1, or 2
* All adverse events associated with any prior surgery and/or intravesical therapy must have resolved to common terminology criteria for adverse events (CTCAE) version 5.0 Grade less than (\<) 2 prior to date of randomization
* Participants must be willing to undergo all study procedures

Exclusion Criteria:

* Presence or history of histologically confirmed, muscle invasive, locally advanced, nonresectable, or metastatic urothelial carcinoma (that is, greater than and equal to \[\>=\] T2)
* Must not have had urothelial carcinoma or histological variant at any site outside of the urinary bladder (that is, urethra, ureter, or renal pelvis). Ta/any T1/CIS of the upper urinary tract (including renal pelvis and ureter) is allowable if treated with complete nephroureterectomy more than 24 months prior to randomization
* Presence of any bladder or urethral anatomic feature (example, urethral stricture) that, in the opinion of the investigator, may prevent the safe insertion, indwelling use, removal of TAR-200 or administration of intravesical BCG. Participants with tumors involving the prostatic urethra in men will be excluded
* A history of clinically significant polyuria with recorded 24-hour urine volumes greater than 4000 milliliters (mL)
* Indwelling catheters are not permitted; however, intermittent catheterization is acceptable

Where it's running

• Mayo Clinic
  Scottsdale, Arizona, United States
• Arkansas Urology
  Little Rock, Arkansas, United States
• VA Long Beach Health Care System
  Long Beach, California, United States
• Genesis Research, LLC - West Coast Urology
  Los Alamitos, California, United States
• Cedars Sinai Medical Center
  Los Angeles, California, United States
• UC Davis Comprehensive Cancer Center
  Sacramento, California, United States

+190 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Principal investigator: Janssen Research & Development, LLC Clinical Trial — Janssen Research & Development, LLC

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Erdafitinib with or without Cetrelimab for muscle-invasive bladder cancer

  This study is testing if a new drug called erdafitinib, alone or with another drug called cetrelimab, can help people with muscle-invasive bladder cancer who can’t take certain chemotherapy drugs before their surgery.

  Recruiting at 19 sites Phase 2 Spanish Oncology Genito-Urinary Group · Clermont-Ferrand and 22 other locations · NCT06511648

• JNJ-101556143 plus Best Supportive Care for metastatic prostate cancer

  This study tests whether adding JNJ-101556143 to standard supportive care helps people with metastatic, hormone-resistant prostate cancer live longer than those who receive placebo plus supportive care.

  Recruiting at 4 sites Phase 3 Janssen Research & Development, LLC · El Paso, Texas and 3 other locations · NCT07906717

• Testing JNJ-101556143 in men with advanced prostate cancer that no longer responds to hormone therapy

  This study tests JNJ-101556143 in men with metastatic, hormone-resistant prostate cancer to see if tumors shrink or disappear.

  Recruiting at 14 sites Phase 2 Janssen Research & Development, LLC · Largo, Florida and 13 other locations · NCT07832292

• Long-Term Guselkumab Use in Adults with Inflammatory Bowel Disease

  This study looks at how long adults with Crohn's disease or ulcerative colitis stay on guselkumab in real-world care.

  Recruiting Janssen Research & Development, LLC · Amiens · NCT07822529

• New treatment option for advanced prostate cancer using JNJ-98768111

  A first-in-human study tests JNJ-98768111 to see how safe it is and find the best dose for people with advanced prostate cancer who have already tried other therapies.

  Recruiting at 6 sites Phase 1 Janssen Research & Development, LLC · Sarasota, Florida and 5 other locations · NCT07746713

• Test of JNJ-95597528 vs placebo in adults with moderate to severe asthma

  This trial checks whether JNJ-95597528 helps adults with moderate to severe asthma when added to their current treatment, compared with a placebo.

  Recruiting at 19 sites Phase 2 Janssen Research & Development, LLC · Westminster, California and 18 other locations · NCT07746687

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.